Finasteride (Proscar/Propecia) - Comprehensive Research Paper

Document Information

• Created: 2025-12-26
• Purpose: Clinical reference for hormone therapy product knowledge
• Paper Number: 57 of 76 (5-Alpha Reductase Inhibitors)

1. Summary

Finasteride is the first 5-alpha reductase inhibitor (5-ARI), developed by Merck and approved by the FDA in two distinct formulations: Proscar (5 mg) for benign prostatic hyperplasia (BPH) on June 19, 1992, and Propecia (1 mg) for male pattern hair loss (androgenetic alopecia) on December 19, 1997. The medication works by competitively inhibiting Type II and Type III 5-alpha reductase enzymes, reducing conversion of testosterone to dihydrotestosterone (DHT) by approximately 70%.

Finasteride addresses conditions driven by DHT, including BPH (where it reduces prostate volume by 20-30%) and androgenetic alopecia (where it arrests hair loss in over 90% and promotes regrowth in 48-66% of men). The medication is taken once daily regardless of indication, with the dose determining the approved use.

The drug has been subject to increasing safety scrutiny. The FDA has added warnings regarding depression and the potential masking of prostate cancer through PSA reduction. Sexual side effects including erectile dysfunction, decreased libido, and reduced ejaculatory volume are well-documented. Post-finasteride syndrome (PFS), a controversial condition characterized by persistent sexual, neuropsychiatric, and physical symptoms after drug discontinuation, remains debated but is increasingly recognized. In 2025, the European Medicines Agency confirmed that suicidal thoughts can occur as a side effect.

Despite these concerns, finasteride remains widely prescribed due to its efficacy, once-daily dosing, and generic availability. Careful patient selection and counseling about potential risks, particularly in younger men and those with psychiatric history, is essential.

Goal Relevance:

• I want to stop my hair from thinning and see some regrowth.
• I'm looking to manage my enlarged prostate and improve urinary symptoms.
• I need a treatment to help with male pattern baldness and prevent further hair loss.
• I want to avoid surgery for my prostate issues by reducing its size.
• I'm interested in a once-daily medication to help with my hair loss.
• I need a solution to improve my urinary flow and reduce the risk of acute urinary retention.
• I'm dealing with hair loss and want a proven medication to help with regrowth.

Goal Archetype Integration

Primary Goal Alignment

When Finasteride Makes Sense

• Hair loss prevention/treatment: Men with androgenetic alopecia (vertex and anterior mid-scalp) seeking to halt progression and potentially regrow hair
• TRT-induced hair loss protection: Men on testosterone replacement therapy who are experiencing or at risk for accelerated hair loss due to elevated DHT
• Symptomatic BPH: Men over 50 with enlarged prostate causing urinary symptoms (frequent urination, weak stream, incomplete emptying)
• BPH surgery prevention: Men wanting to avoid TURP or other surgical interventions through medical management
• DHT-driven acne: Off-label use in men with severe DHT-mediated sebum production (not first-line)

When to Choose Something Else

• Rapid symptom relief for BPH: Alpha-blockers (tamsulosin, alfuzosin) work within days vs. 6-12 months for finasteride - use alpha-blockers for acute relief, finasteride for long-term size reduction
• Female pattern hair loss: Not FDA-approved for women; other options (minoxidil, spironolactone) preferred due to teratogenicity risk
• History of depression or sexual dysfunction: Post-finasteride syndrome risk warrants careful consideration; alternatives include topical minoxidil, low-level laser therapy, or hair transplantation
• Need for maximum DHT suppression: Dutasteride achieves 90-95% DHT reduction vs. 70% with finasteride (off-label for hair loss in US)
• Prostate cancer screening context: If maintaining accurate PSA monitoring is critical, be aware of 50% PSA reduction requiring adjustment

2. Mechanism of Action

Primary Mechanism: 5-Alpha Reductase Inhibition

Finasteride acts as a competitive, specific inhibitor of 5-alpha reductase, the intracellular enzyme that converts testosterone to dihydrotestosterone (DHT).

Enzyme Specificity:

• Primary target: Type II 5-alpha reductase (nuclear-bound, prostatic stromal cells)
• Also inhibits: Type III 5-alpha reductase
• Minimal activity: Type I 5-alpha reductase (skin, liver)

Tissue Distribution of 5-Alpha Reductase:

• Type I: Predominantly in sebaceous glands, liver
• Type II: Prostate, seminal vesicles, hair follicles, liver
• Type III: Brain, skin, other tissues

DHT Reduction

Quantitative Effects:

• Serum DHT reduction: ~68-70%
• Scalp DHT reduction: ~64%
• Prostatic DHT reduction: ~80-90%
• Testosterone levels: Increase 10-20% (compensatory)

Dose-Response:

• 0.2 mg daily: 55% DHT suppression
• 1 mg daily: 65-68% DHT suppression
• 5 mg daily: 69-70% DHT suppression

Therapeutic Consequences

In BPH:

• Reduced DHT leads to prostatic epithelial apoptosis
• Prostate volume reduction of 20-30%
• Improved urinary flow and symptoms
• Reduced risk of acute urinary retention
• Reduced need for surgical intervention

In Androgenetic Alopecia:

• Reduced DHT at follicular level
• Prevention of further miniaturization
• Reversal of miniaturization in responsive follicles
• Hair regrowth in many patients

Mechanism Distinction from Antiandrogens

Unlike antiandrogens (bicalutamide, spironolactone), finasteride does NOT:

• Block the androgen receptor
• Affect testosterone activity at receptors
• Cause antiandrogen withdrawal syndrome
• Produce feminizing effects at typical doses

Neurosteroid Effects

5-alpha reductase also converts other steroids:

• Progesterone → Allopregnanolone (neurosteroid)
• Reduction in neurosteroid synthesis may contribute to:
  • Mood effects
  • Sexual function changes
  • Post-finasteride syndrome (theorized)

3. FDA-Approved Indications

Indication 1: Benign Prostatic Hyperplasia (BPH)

Brand Name: Proscar Approved: June 19, 1992 Dose: 5 mg once daily

Approved Uses:

• Treatment of symptomatic BPH in men with enlarged prostate
• To improve symptoms
• Reduce risk of acute urinary retention
• Reduce risk of need for surgical intervention (TURP)

Combination Therapy:

• May be used with alpha-blockers (doxazosin, tamsulosin)
• MTOPS trial demonstrated combination superiority

Indication 2: Androgenetic Alopecia (Male Pattern Baldness)

Brand Name: Propecia Approved: December 19, 1997 Dose: 1 mg once daily

Approved Uses:

• Treatment of male pattern hair loss (vertex and anterior mid-scalp)
• In MEN only
• NOT approved for women

Efficacy Data from Pivotal Trials:

• Hair loss arrest: >90% of men
• Hair regrowth at 12 months: 48%
• Hair regrowth at 48 months: 66%

Non-FDA-Approved Formulations (2024 FDA Alert)

Compounded Topical Finasteride:

• NOT FDA-approved
• FDA issued 2024 alert about safety concerns
• Dozens of adverse event reports received
• Safety, effectiveness, and manufacturing quality not evaluated

Off-Label Uses

• Female pattern hair loss (controversial, teratogenic risk)
• Hirsutism
• Transgender hormone therapy (feminizing)
• Prostate cancer prevention (NOT approved; see prostate cancer risk warning)

4. Dosing and Administration

FDA-Approved Dosing

BPH (Proscar):

• Dose: 5 mg once daily
• May be taken with or without food
• Continuous long-term therapy required

Androgenetic Alopecia (Propecia):

• Dose: 1 mg once daily
• May be taken with or without food
• Minimum 3 months before initial response
• 12 months for full assessment of efficacy
• Hair loss may resume upon discontinuation

Administration Guidelines

General:

• Tablets should be swallowed whole
• Do not crush, break, or chew (especially relevant for women/pregnancy)
• Consistent daily administration recommended
• Can be taken at any time of day

Missed Dose:

• Take as soon as remembered
• If close to next dose, skip missed dose
• Do not double up

Low-Dose Considerations

Research on Lower Doses:

• 0.2 mg achieves 55% DHT suppression
• Similar efficacy demonstrated at 0.2 mg and above
• Not FDA-approved at lower doses
• Some clinicians use lower doses off-label to minimize side effects

Treatment Duration

BPH:

• Long-term therapy (years)
• Benefits may take 6-12 months to manifest
• Continued therapy required to maintain benefits

Hair Loss:

• Indefinite therapy required to maintain benefit
• Hair loss resumes within 12 months of discontinuation
• No "cure" - symptomatic treatment only

Age-Stratified Dosing

Key Age Considerations:

• Young men (18-35): Higher vigilance for psychological/sexual side effects; 55% of PFS patients had prior psychiatric diagnosis - screen carefully
• Men on TRT: 1 mg daily typically adequate to preserve hair while on testosterone therapy
• Elderly (65+): Half-life prolongs to ~8 hours vs. 5-6 hours, but clinical significance minimal; no dose reduction needed
• Men >50 with BPH: Consider combination therapy with alpha-blocker for faster symptom relief while waiting for finasteride effect (6-12 months)

Sex-Specific Considerations

Males:

• Standard dosing applies across age groups
• DHT reduction of 65-70% at 1 mg, 69-70% at 5 mg
• Monitor for sexual side effects, depression, breast changes
• Discuss PFS risk, especially in younger men or those with psychiatric history

Females (Off-Label - Significant Cautions):

• NOT FDA-approved for women
• Absolutely contraindicated in pregnancy (Category X - feminization of male fetus)
• If considered postmenopausal: 2.5-5 mg daily used off-label (results less dramatic than men)
• Requires reliable contraception if any pregnancy potential
• Consider alternatives first: topical minoxidil, spironolactone

Combination Therapies

BPH:

• Finasteride + alpha-blocker (doxazosin, tamsulosin, alfuzosin)
• MTOPS trial: Combination superior to monotherapy

Hair Loss:

• Finasteride + topical minoxidil
• Additive effects reported
• Different mechanisms allow combination

5. Pharmacokinetics

Absorption

• Bioavailability: ~65% (oral)
• Tmax: 2 hours
• Food Effect: No clinically significant effect
• Steady State: Approximately 5 days of daily dosing

Distribution

• Protein Binding: ~90% (primarily albumin)
• Volume of Distribution: 76 L
• Tissue Penetration:
  • Crosses blood-brain barrier
  • Enters prostatic tissue
  • Found in semen (minimal amounts)

Semen Exposure:

• Finasteride is present in semen
• Amounts are minimal (nanogram range)
• Theoretically could affect male fetus if pregnant woman exposed to semen
• Clinical significance uncertain

Metabolism

• Primary Route: Hepatic metabolism
• Enzymes: CYP3A4 (primary), CYP3A5
• Metabolites: Two metabolites with minimal 5-AR inhibitory activity
• No active metabolites of clinical significance

Elimination

• Half-Life:
  • Younger adults: 5-6 hours
  • Elderly (>70 years): 8 hours
• Excretion:
  • Feces: 57% (as metabolites)
  • Urine: 39% (as metabolites)
• Unchanged Drug: Minimal urinary excretion

Special Population Pharmacokinetics

Hepatic Impairment:

• Not studied extensively
• Use caution in hepatic dysfunction
• Metabolism is hepatic

Renal Impairment:

• No dose adjustment required
• Minimal renal excretion of parent drug

Elderly:

• Half-life prolonged to ~8 hours
• No dose adjustment recommended
• Clinical significance minimal

Drug Accumulation

• Modest accumulation at steady state
• Steady state achieved in ~5 days
• No significant accumulation concerns with chronic use

6. Side Effects and Adverse Reactions

Sexual Dysfunction (Most Common)

Well-Documented Sexual Side Effects:

• Erectile dysfunction: 3-8% (vs. 1-2% placebo)
• Decreased libido: 2-6%
• Reduced ejaculatory volume: 1-4%
• Ejaculation disorder: 1-2%
• Orgasm disorder: Reported

Characteristics:

• Usually reversible upon discontinuation
• May persist in some patients (see Post-Finasteride Syndrome)
• More commonly reported in hair loss population (younger men, more aware)

Psychiatric Effects

FDA Warning Added: Depression is included in package insert warnings.

Reported Effects:

• Depression
• Anxiety
• Cognitive changes ("brain fog")
• Suicidal ideation (EMA confirmed 2025)

2025 EMA Update: The European Medicines Agency confirmed that suicidal thoughts can occur as a side effect. Majority of reports involved 1 mg dosage for hair loss.

Post-Finasteride Syndrome (PFS)

Definition: Persistent sexual, neuropsychiatric, and physical symptoms lasting ≥3 months after finasteride discontinuation.

Reported Symptoms:

• Persistent erectile dysfunction
• Loss of libido
• Loss of genital sensitivity
• Reduced ejaculate
• Depression and anxiety
• Memory problems
• Emotional detachment
• Insomnia

Scientific Status:

• Remains controversial
• Not universally recognized as distinct syndrome
• Some studies suggest real physiological basis
• Others suggest nocebo effect or pre-existing conditions
• 2019 BMJ editorial called it "ill defined and controversial"

Risk Factors Suggested:

• History of depression (55% of PFS patients had prior psychiatric diagnosis)
• May occur even with low doses and short exposure
• Individual susceptibility unclear

Other Side Effects

Gynecomastia/Breast Effects:

• Breast tenderness: 0.5-2%
• Gynecomastia: 0.5-1%
• Usually reversible

Dermatologic:

• Rash (uncommon)
• Pruritus

General:

• Asthenia (rare)
• Dizziness (rare)

Prostate Cancer Risk Warning

FDA Warning: 5-alpha reductase inhibitors lower PSA, which could mask prostate cancer detection. Additionally, there may be increased risk of high-grade prostate cancer.

PSA Considerations:

• PSA reduced by approximately 50% during therapy
• For screening, multiply measured PSA by 2
• Any PSA rise during therapy warrants evaluation

7. Drug Interactions - Comprehensive

Cytochrome P450 Interactions

CYP3A4 Substrate: Finasteride is metabolized primarily by CYP3A4.

CYP3A4 Inhibitors (may increase finasteride levels):

• Ketoconazole
• Itraconazole
• Ritonavir
• Clarithromycin
• Grapefruit juice

CYP3A4 Inducers (may decrease finasteride levels):

• Rifampin
• Phenytoin
• Carbamazepine
• St. John's Wort

Clinical Significance:

• Interactions generally not clinically significant
• No dose adjustments typically required
• Wide therapeutic index

Prescription Medication Interactions

Critical Interaction: Finasteride + TRT (Testosterone Replacement Therapy)

This is the most clinically important interaction for hormone optimization protocols.

Why Combine Finasteride with TRT:

• TRT increases both testosterone AND DHT levels
• Elevated DHT accelerates male pattern baldness in genetically susceptible men
• Only 5-17% of men on TRT + finasteride experience mild hair loss in year 1 (vs. much higher without finasteride)
• Finasteride preserves hair while allowing testosterone optimization benefits

Mechanism When Combined:

• TRT raises testosterone (therapeutic goal)
• Without finasteride: More testosterone converts to DHT via 5-alpha reductase
• With finasteride: DHT conversion blocked by 65-70% even with elevated T
• Net effect: Higher testosterone, lower/normal DHT, hair preservation

Expected Hormonal Changes on TRT + Finasteride:

Clinical Protocol for TRT + Finasteride:

1. Dose: 1 mg daily finasteride is adequate (5 mg provides no additional DHT suppression benefit)
2. Timing: Can start simultaneously with TRT or add when hair thinning observed
3. Monitoring:
   • Check testosterone, DHT, estradiol at baseline, 6 weeks, 3 months
   • PSA baseline and periodic (multiply by 2 for true value)
   • Assess hair status with photographs
4. Team approach: "Finasteride with TRT should be managed alongside the patient's endocrine or urology team" (Baylor Medicine guidance)

Potential Issues with Combination:

• Combined hormonal effects may increase estradiol (monitor for gynecomastia)
• Some men report cumulative sexual side effects
• DHT has some androgenic benefits (strength, libido) that may be reduced

Post-Finasteride Syndrome (PFS) Awareness in Drug Selection

Critical Consideration for Patient Counseling:

When selecting finasteride, particularly in young men or those on complex hormone protocols, awareness of PFS risk is essential:

What We Know (2024-2025 Evidence):

• A 2020 meta-analysis of 34 studies found 5-ARI use increases PFS-like adverse effects risk by 1.87x (95% CI: 1.64-2.14)
• A 2025 review in International Journal of Impotence Research concluded PFS represents "a true clinical entity" with "non-neglectable physical and psychological symptoms"
• EMA confirmed suicidal thoughts as a potential side effect (2025)
• 55% of PFS patients had prior psychiatric diagnosis (screening important)

What Remains Uncertain:

• Exact incidence (rare, but difficult to estimate due to self-reporting bias)
• Underlying mechanism (neurosteroid depletion, epigenetic changes, androgen receptor alterations proposed)
• Whether true pathophysiology vs. nocebo effect in susceptible individuals
• Effective treatments (none proven)

Risk Mitigation Strategies:

1. Screen for psychiatric history before starting
2. Discuss potential persistent effects during informed consent
3. Consider lower doses (0.2-0.5 mg) which achieve meaningful DHT suppression
4. Avoid in men with pre-existing sexual dysfunction or depression
5. Consider alternatives (minoxidil, laser, transplant) in high-risk individuals

Other Compound Interactions (Stacking)

Supplement Interactions

Food/Timing Interactions

Drug-Lab Interactions

PSA (Critical):

• Reduces PSA by approximately 50% (40-50% range)
• Must multiply measured PSA by 2 for interpretation
• After >1 year of therapy, adjustment factor may need to increase to 2.5
• Any rise during therapy is concerning and warrants urological evaluation
• Baseline PSA REQUIRED before initiating

Other Hormones:

• Slight increase in testosterone (10-20% - compensatory)
• Slight increase in LH (compensatory)
• Decreased DHT by 65-70% (therapeutic effect)
• Possible slight increase in estradiol (aromatization of elevated T)

8. Contraindications

Absolute Contraindications

Women:

• Not approved for use in women
• Contraindicated in women of childbearing potential
• Teratogenic risk (feminization of male fetus)

Pregnancy (Category X):

• Absolutely contraindicated
• Can cause abnormalities of external genitalia in male fetus
• Women should not handle crushed/broken tablets
• Pregnant women should avoid semen exposure (theoretical)

Hypersensitivity:

• Known hypersensitivity to finasteride
• Hypersensitivity to any component

Pediatric Use:

• Not indicated for use in children
• Safety and efficacy not established

Relative Contraindications

History of Mood Disorders:

• Use with caution in patients with depression history
• FDA warning about depression
• Careful risk-benefit assessment required

History of Sexual Dysfunction:

• Pre-existing sexual dysfunction may be worsened
• Assess baseline sexual function
• Discuss potential for adverse effects

Liver Disease:

• Hepatic metabolism
• Use caution in hepatic impairment
• No specific dose adjustment, but caution warranted

Warnings and Precautions

Prostate Cancer Screening:

• PSA reduced by therapy
• Baseline PSA before initiating
• Multiply measured PSA by 2 during therapy
• Any PSA increase warrants evaluation

Mood and Suicidality:

• Monitor for mood changes
• EMA confirmed suicidal thoughts as potential side effect
• Counsel patients about psychiatric symptoms

Sexual Function:

• Counsel about potential sexual side effects
• May persist after discontinuation in some patients

9. Special Populations

Women

Not Recommended:

• Finasteride is not FDA-approved for women
• Contraindicated in women who are or may become pregnant
• Off-label use for female pattern hair loss is controversial

If Used Off-Label (Not Recommended):

• Must ensure reliable contraception
• Pregnancy testing required
• Teratogenic risk category X
• Lower doses sometimes used (theoretical)

Pregnant Women

Absolutely Contraindicated:

• Category X
• Causes abnormalities of male fetus genitalia
• Hypospadias documented in animal studies
• Women must not handle crushed tablets

Semen Exposure:

• Small amounts of finasteride in semen
• Pregnant women advised to avoid semen exposure
• Clinical significance debated but precaution recommended

Pediatric Patients

• Not indicated in children
• Safety and efficacy not established
• No approved pediatric uses

Geriatric Patients

Pharmacokinetic Changes:

• Half-life prolonged to ~8 hours (vs. 5-6 hours in younger adults)
• No dose adjustment required
• Efficacy maintained

Clinical Considerations:

• Primary BPH population is elderly men
• Monitor PSA carefully (prostate cancer screening)
• Assess for polypharmacy interactions

Transgender Individuals (Off-Label)

Feminizing Hormone Therapy:

• Sometimes used to reduce DHT in transgender women
• Usually combined with estrogen
• May help with male pattern hair loss prevention
• Not first-line antiandrogen (spironolactone more common)

Dosing:

• 1-5 mg daily (off-label)
• Typically lower doses if combined with other antiandrogens

Patients with Depression History

Special Caution Required:

• 55% of PFS patients had prior psychiatric diagnosis
• FDA warning about depression
• EMA confirmed suicidal thoughts risk (2025)
• Careful risk-benefit discussion essential
• Consider alternatives or close monitoring

10. Monitoring Parameters

Pre-Treatment Assessment

Required:

• Digital rectal exam (BPH patients)
• PSA baseline (multiply measured value by 2 during therapy)
• Assessment of urinary symptoms (BPH)
• Hair loss pattern documentation (alopecia)

Recommended:

• Baseline sexual function assessment
• Mental health screening
• Liver function tests (if hepatic concerns)

During Treatment

BPH Monitoring:

• PSA: 6-12 months, then annually
• Digital rectal exam: Annually
• Symptom assessment (IPSS score)
• Uroflow if indicated

Hair Loss Monitoring:

• Clinical assessment: 3, 6, 12 months
• Photographs for comparison
• Patient satisfaction assessment
• Continue if benefit; reassess at 12 months

Safety Monitoring

Sexual Function:

• Ask about erectile function, libido
• Document any changes
• Counsel about potential persistence

Mental Health:

• Screen for depression, anxiety
• Ask about mood changes
• Assess suicidal ideation (EMA warning)

PSA Interpretation (Critical):

• Multiply measured PSA by 2 during therapy
• Any increase from nadir concerning
• Refer for urological evaluation if PSA rises

Discontinuation Monitoring

If Discontinuing:

• Sexual function: May improve, may persist
• Hair loss: Resumes within 12 months
• PSA: Returns to pre-treatment baseline
• Mood: Monitor for changes

Patient Education

Counsel patients to report:

• Changes in sexual function
• Mood changes, depression
• Suicidal thoughts
• Breast changes (tenderness, enlargement)
• Testicular pain
• Difficulty urinating (BPH patients)

Bloodwork Impact & Monitoring

Expected Marker Changes

Monitoring Schedule

Special Monitoring for TRT + Finasteride Protocols

Red Flags in Labs

Labs + Symptoms Integration

Marker-Based Dose Adjustment

Adjustment by Baseline Markers

Adjustment by On-Treatment Response

11. Cost and Availability

Brand and Generic Availability

Brand Names:

• Proscar (Merck) - 5 mg for BPH
• Propecia (Merck) - 1 mg for hair loss

Generic Availability:

• Generic finasteride available since 2006 (Proscar patent expiration)
• Multiple generic manufacturers
• Significant cost savings with generics

Typical Pricing (United States, 2024)

Generic Finasteride 1 mg (30 tablets):

• Retail: $15-30
• With discount programs: $5-15
• Very affordable medication

Generic Finasteride 5 mg (30 tablets):

• Retail: $15-40
• With discount programs: $10-20
• Some patients split 5 mg tablets for cost savings (off-label)

Brand Propecia 1 mg (30 tablets):

• AWP: ~$80-100
• Rarely prescribed due to generic availability

Brand Proscar 5 mg (30 tablets):

• AWP: ~$150-200
• Rarely prescribed due to generic availability

Insurance Coverage

BPH (Proscar/5 mg):

• Generally covered by insurance
• Generic tier preferred
• May require step therapy after alpha-blocker

Hair Loss (Propecia/1 mg):

• Often NOT covered (considered cosmetic)
• Cash pay common
• Generic makes it affordable regardless

International Availability

• Widely available globally
• Generic availability in most countries
• Lower prices outside United States
• Various brand names by country

Cost-Saving Strategies

Pill Splitting:

• Some patients split 5 mg tablets into quarters for hair loss
• Cost savings significant
• Not FDA-approved approach
• Uneven splitting affects dosing accuracy

Online Pharmacies:

• Legitimate online pharmacies offer competitive pricing
• Ensure pharmacy verification
• Beware of counterfeit products

Compounded Topical (Warning)

2024 FDA Alert:

• Compounded topical finasteride products are NOT FDA-approved
• Safety and efficacy not evaluated
• Manufacturing quality not assured
• Adverse events reported

12. Clinical Evidence Summary

BPH Clinical Trials

Pivotal Proscar Trials:

• Demonstrated prostate volume reduction of 20-30%
• Improved urinary symptoms (IPSS score)
• Reduced risk of acute urinary retention by ~57%
• Reduced need for surgery by ~55%

MTOPS Trial (Medical Therapy of Prostatic Symptoms):

• Combination finasteride + doxazosin superior to either alone
• Reduced disease progression by 66%
• Gold standard evidence for combination therapy

PLESS Trial (Proscar Long-term Efficacy and Safety Study):

• 4-year study, 3,040 men
• Confirmed long-term efficacy and safety
• Reduced surgery and acute urinary retention

Hair Loss Clinical Trials

Pivotal Propecia Trials:

• 5-year studies in men with male pattern baldness
• Hair loss arrest: >90% of men
• Hair regrowth at 12 months: 48%
• Hair regrowth at 24 months: 66%
• Benefit maintained with continued use

Vertex Hair Count Studies:

• 1 mg daily: Significant increase in hair count vs. placebo
• Effect evident by 3 months
• Maximum effect at 1-2 years
• Maintained with continued therapy

Prostate Cancer Prevention Trial (PCPT)

Key Finding:

• Finasteride reduced prostate cancer risk by 24.8%
• However: Increased detection of high-grade cancers
• Led to FDA warning, NOT approved for prevention
• Debate about detection bias vs. true increased risk

Post-Finasteride Syndrome Research

Supporting Evidence:

• Multiple case series documenting persistent symptoms
• Neurosteroid hypothesis (reduced allopregnanolone)
• Studies showing androgen receptor changes

Skeptical Perspectives:

• 2019 BMJ editorial: "ill defined and controversial"
• Nocebo effect hypothesis
• Pre-existing conditions in many patients
• No proven treatments

13. Comparison with Alternatives

Finasteride vs. Dutasteride

Finasteride vs. Alpha-Blockers (BPH)

Finasteride vs. Minoxidil (Hair Loss)

Alternatives for Hair Loss

1. Minoxidil - Topical, OTC, different mechanism
2. Low-level laser therapy - FDA-cleared devices
3. Hair transplantation - Surgical option
4. Platelet-rich plasma (PRP) - Emerging therapy
5. Dutasteride - More potent 5-ARI (off-label for hair loss)

Protocol Integration

Stacking with Other Compounds

Common Stacks

Timing Considerations

Finasteride vs. Dutasteride Decision Matrix

Evidence Update (2024-2025):

• Systematic review found dutasteride 0.5 mg daily superior to finasteride 1 mg in hair count and regrowth
• Phase II study (2025) showed dutasteride topical 0.05% more effective than oral finasteride 1 mg
• Thrice-weekly dutasteride showed greater improvement than once-daily finasteride (35% vs 21% moderate-to-marked improvement)

Clinical Decision:

• Start with finasteride (FDA-approved, faster clearance, established safety data)
• Consider dutasteride switch if: inadequate response after 12 months, need maximum DHT suppression, or tolerating finasteride well but want enhanced efficacy

Integration with TRT Protocols

Standard TRT + Hair Preservation Protocol

If Hair Loss Progresses Despite Finasteride + TRT

1. Verify compliance (most common issue)
2. Check DHT level - if >50% baseline, consider dutasteride
3. Add topical minoxidil 5% twice daily
4. Consider low-level laser therapy (adjunct)
5. Hair transplant consultation if stable hair loss pattern

Integration with Pillars

Special Protocol: Post-Finasteride Syndrome Risk Mitigation

For patients concerned about PFS but wanting DHT reduction:

1. Pre-treatment screening: PHQ-9 depression screen; sexual function baseline (IIEF-5)
2. Start low: 0.2 mg daily (55% DHT suppression; achievable by splitting 1 mg tablets)
3. Gradual titration: Increase to 0.5 mg at 4 weeks if tolerated, then 1 mg at 8 weeks if desired
4. Early warning monitoring: Weekly self-assessment of mood, libido, erectile function for first 8 weeks
5. Clear exit criteria: Stop immediately if: new depression, persistent ED, new anxiety; most side effects reverse with discontinuation
6. Alternative readiness: Have minoxidil available as backup if finasteride discontinued

14. Storage and Handling

Storage Requirements

Temperature:

• Store at controlled room temperature: 15-30°C (59-86°F)
• Protect from excessive heat

Environment:

• Keep in original container
• Protect from moisture
• Keep container tightly closed

Light:

• No specific light protection required
• Standard packaging adequate

Handling Precautions

Critical: Pregnancy Warning:

• Women who are or may become pregnant MUST NOT handle crushed or broken tablets
• Finasteride is absorbed through skin
• Can cause abnormalities in male fetus

Healthcare Workers:

• Use gloves when handling broken tablets
• Intact tablets may be handled with minimal risk
• Avoid crushing or splitting in presence of pregnant women

Pharmacist Considerations:

• Do not split or crush tablets for pregnant women
• Counsel patients about handling precautions
• Pregnancy category X

Dispensing Considerations

Packaging:

• Proscar: Bottles of 30, 100 tablets
• Propecia: Bottles of 30, 90 tablets
• Blister packaging available

Tablet Integrity:

• Film-coated tablets protect from contact
• Coating minimizes dermal absorption risk
• Do not crush, split, or chew (especially for pregnancy protection)

Pill Splitting:

• Though some patients split 5 mg tablets
• Not officially recommended
• Creates handling risk if done improperly

Stability

Shelf Life:

• Typically 2-3 years from manufacture
• Check expiration date

After Opening:

• Use within expiration date
• No special post-opening requirements
• Maintain tight closure

15. References

Primary Literature

1. FDA Prescribing Information. Proscar (finasteride) tablets. Merck. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. FDA Prescribing Information. Propecia (finasteride) tablets. Merck.

3. Finasteride. StatPearls. NCBI Bookshelf. 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK513329/

4. 5α-Reductase Inhibitors. StatPearls. NCBI Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK555930/

Clinical Trials

5. McConnell JD, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998.

6. MTOPS Research Group. The effect of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia. N Engl J Med. 2003.

7. Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998.

Post-Finasteride Syndrome

8. Post-finasteride syndrome. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7253896/

9. Post‐finasteride syndrome: real or myth? Trends in Urology & Men's Health. 2024. Available at: https://onlinelibrary.wiley.com/doi/10.1002/tre.972

10. Finasteride and sexual side effects. PMC. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3481923/

Regulatory Updates

11. FDA. 5-Alpha Reductase Inhibitor Information. Available at: https://www.fda.gov/drugs/information-drug-class/5-alpha-reductase-inhibitor-information

12. European Medicines Agency. 2025 review confirming suicidal thoughts as side effect.

13. Finasteride for Hair Loss: Results, Side Effects, and 2025 FDA Topical Alert. Healthon.com. Available at: https://healthon.com/blogs/journal/finasteride

Additional Resources

14. DrugBank. Finasteride. Available at: https://go.drugbank.com/drugs/DB01216

15. Drugs.com. Finasteride: Uses, Dosage, Side Effects, Warnings. Available at: https://www.drugs.com/finasteride.html

16. Wikipedia. Finasteride. Available at: https://en.wikipedia.org/wiki/Finasteride

17. A new look at the 5alpha-reductase inhibitor finasteride. PubMed. 2006.

Document Completion: 2025-12-26 Status: PAPER 57 OF 76 COMPLETE Next Paper: #58 - Dutasteride